Sabinsa Corporation announces
the development of a new drug to fight African sleeping
sickness. A patent application is in the process of being
submitted to the United States Patent and Trademark Office.
Sabinsa collaborated with its Indian associate, Sami Labs
Ltd. in the process development of this project, said Dr.
N. Kalyanam, President of the SAMI/SABINSA R & D group.
African sleeping sickness (Trypanosomiasis)
is a parasitic infection that spreads through the bite of
the tsetse fly. Initial symptoms include low-grade fever,
painful joints and skin irritation. The parasites carrying
the disease soon cross the blood-brain barrier, inducing
hallucinations, behavioral changes and severe pain, with
the victim lapsing into a coma. If left untreated, the disease
is 100% fatal.
Trypanosomiasis was eradicated in the 1960’s.
However, there has been a recent resurgence in epidemic
proportions. Epidemiologists estimate that about 450,000
people in central Africa are infected. This parasitic disease
has spread three times faster than the human immunodeficiency
virus, HIV, that causes AIDS. Only an estimated 7% of the
60 million people believed to be at risk of infection in
Africa, have access to health care.
Very few drugs are currently available to treat
African sleeping sickness. These have significant disadvantages,
including severe toxic and often fatal side effects. Additionally,
most of these drugs have to be administered by injection,
posing practical difficulties in areas with poor health
care facilities and hygiene. Scientific evidence also suggests
that the parasite causing the disease is becoming progressively
resistant to melarsoprol, the most commonly used medication.
Treatment of the disease has not changed much in the last
50 years, with very little research being directed toward
the human form of African sleeping sickness. The research
project at SABINSA/SAMI is therefore dedicated to serving
an immediate need for developing effective, safe and economical
drugs to combat this resurgent scourge.
Sabinsa Corporation is an application-oriented
manufacturing and marketing company which manufacturers
and supplies Phytonutrients, Ayurvedic herbal extracts and
specialty fine chemicals used for nutritional, pharmaceutical
and food products. Sabinsa distinguishes itself by its extensive
research support for its customers and products, and the
scientific credentials of its key technical staff.